The emerging utility of animal models of chronic neurodegenerative diseases

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 1, 2001, Pages 125-132

  Kahle, Philipp J ^a   Haass, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

aggregation; Alzheimer's disease; amyloidogenesis; frontotemporal dementia; Lewy body; neurodegeneration; neurofibrillary tangle; Parkinsons disease; senile plaque; synuclein; tau; ubiquitin

Indexed keywords

EID: 33748052069     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.5.1.125     Document Type: Review

References (58)

1. FRATIGLIONI L, DE RONCHI D, AGUERO-TORRES H: Worldwide prevalence and incidence of dementia. Drugs Aging (1999) 15(5):365-375.
2. HENDRIE HC: Epidemiology of dementia and Alzheimer's disease. Am. J. Geriatr. Psychiatry (1998) 6(2 Suppl. 1):S3-18.
3. NORDBERG A, SVENSSON AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. (1998) 19(6):465-480.
4. SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y: Donepezil hydrochloride (E2020) and other acetyl-cholinesterase inhibitors. Curr. Med. Chem. (2000) 7(3):303-339.
5. TRENKWALDER C, SCHWARZ J, GEBHARD J et al.: Starnberg trial on epidemiology of Parkinsonism and hypertensioninthe elderly. PrevalenceofParkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch. Neurol. (1995) 52(10):1017-1022.
6. SCHRAG A, BEN-SHLOMO Y, QUINN NP: Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet (1999) 354(9192):1771-1775.
7. POEWE W: Adjuncts to levodopa therapy: dopamine agonists. Neurology (1998) 50(6 Suppl. 6):S23-26.
8. FOLLETT KA: The surgical treatment of Parkinson's disease. Ann. Rev. Med. (2000) 51:135-147.
9. KOO EH, LANSBURY PT, JR., KELLY JW: Amyloid diseases: abnormal protein aggregation in neurode-generation. Proc. Natl. Acad. Sci. USA (1999) 96(18):9989-9990.
10. JOHNSON WG: Late-onset neurodegenerative diseases-the role of protein insolubility. J. Anat. (2000) 196(Pt 4):609-616.
11. WAGGIE KS, KAHLE PJ, TOLWANI RJ: Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review. Lab. Anim. Sci. (1999) 49(4):358-362.
12. PRICE DL, TANZI RE, BORCHELT DR, SISODIA SS: Alzheimer's disease: genetic studies and transgenic models. Ann. Rev. Genet. (1998) 32:461-493.
13. VAN LEUVEN F: Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. (2000) 61(3):305-312.
14. LEVITAN D, DOYLE TG, BROUSSEAU Det al.: Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA (1996) 93(25):14940-14944.
15. BAUMEISTER R, LEIMER U, ZWECKBRONNER I, JAKUBEK C, GRÜNBERG J, HAASS C: Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct. (1997) 1(2):149-159.
16. FOSSGREEN A, BRUCKNER B, CZECH C, MASTERS CL, BEYREUTHER K, PARO R: Transgenic Drosophila expressing human amyloid precursor protein show g-secretase activity and a blistered-wing phenotype. Proc. Natl. Acad. Sci. USA (1998) 95(23):13703-13708.
17. STRUHL G, GREENWALD I: Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature (1999) 398(6727):522-525.
18. YE Y, LUKINOVA N, FORTINI ME: Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants. Nature (1999) 398(6727):525-529.
19. GUO Y, LIVNE-BAR I, ZHOU L, BOULIANNE GL: Drosophila presenilin is required for neuronal differentiation and affects Notch subcellular localization and signaling. J. Neurosci. (1999) 19(19):8435-8442.
20. GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overex-pressing V717F β-amyloid precursor protein. Nature (1995) 373(6514):523-527.
21. ROCKENSTEIN EM, MCCONLOGUE L, TAN H, POWER M, MASLIAH E, MUCKE L: Levels and alternative splicing of amyloid P protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J. Biol. Chem. (1995) 270 (47):28257-28267.
22. MURRELL J, FARLOW M, GHETTI B, BENSON MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 254 (5028):97-99.
23. MASLIAH E, SISK A, MALLORY M, MUCKE L, SCHENK D, GAMES D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F P-amyloid precursor protein and Alzheimer's disease. J. Neurosci. (1996) 16 (18):5795-5811.
24. STRITTMATTER WJ, SAUNDERS AM, SCHMECHEL D et al: Apolipoprotein E high-avidity binding to P-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1993) 90(5):1977-1981.
25. BALES KR, VERINA T, DODEL RC et al.: Lack of apolipoprotein E dramatically reduces amyloid P-peptide deposition. Nature Genet. (1997) 17(3):263-264.
26. BALES KR, VERINA T, CUMMINS DJ et al.: Apolipoprotein Eis essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1999) 96 (26):15233-15238.
27. HOLTZMAN DM, BALES KR, TENKOVA T et al.: Apolipoprotein Eisoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2000) 97 (6):2892-2897.
28. DODART JC, MEZIANE H, MATHIS C, BALES KR, PAUL SM, UNGERER A: Behavioral disturbances in transgenic mice overexpressing the V717F P-amyloid precursor protein. Behav. Neurosci. (1999) 113 (5):982-990.
29. CHEN G, CHEN KS, KNOX J et al: A learning deficit related to age and P-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2000) 408:975-979.
30. SCHENK D, BARBOUR R, DUNN W et al: Immunization with amyloid-P attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400 (6740):173-177.
31. WEINER HL, LEMERE CA, MARON R et al: Nasal administration of amyloid-P peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. (2000) 48 (4):567-579.
32. BARD F, CANNON C, BARBOUR R et al: Peripherally administered antibodies against amyloid P-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. (2000) 6(8):916-919.
33. MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982-985.
34. JANUS C, PEARSON J, MCLAURIN J et al.: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979-982.
35. SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(6738 Suppl):A23-31.
36. MULLAN M, CRAWFORD F, AXELMAN K et al.: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nature Genet. (1992) 1(5):345-347.
37. HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science (1996) 274(5284):99-102.
38. IRIZARRY MC, MCNAMARA M, FEDORCHAK K, HSIAO K, HYMAN BT: APPSwe transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. (1997) 56(9):965-973.
39. STURCHLER-PIERRAT C, ABRAMOWSKI D, DUKE M et al.: Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. Sci. USA (1997) 94(24):13287-13292.
40. CALHOUN ME, WIEDERHOLD K-H, ABRAMOWSKI Det al.: Neuron loss in APP transgenic mice. Nature (1998) 395(6704):755-756.
41. SPITTAELS K, VAN DEN HAUTE C, VAN DORPE J et al.: Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. (1999) 155(6):2153-2165.
42. PROBST A, GÖTZ J, WIEDERHOLD KH et al.: Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. (2000) 99(5):469-481.
43. HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393(6686):702-705.
44. DUMANCHIN C, CAMUZAT A, CAMPION D et al.: Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotem-poral dementia and parkinsonism. Hum. Mol. Genet. (1998) 7(11):1825-1829.
45. CLARK LN, POORKAJ P, WSZOLEK Z et al.: Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegen-erative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA (1998) 95(22):13103-13107.
46. LEWIS J, MCGOWAN E, ROCKWOOD J et al: Neurofibril lary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet. (2000) 25 (4):402-405.
47. GÖTZ J, CHEN F, BARMETTLER R, NITSCH RM: Tau filament formation in transgenic mice expressing P301Ltau. J. Biol. Chem. (2001) 276 (1):529-534.
48. TOLWANI RJ, JAKOWEC MW, PETZINGER GM, GREEN S, WAGGIE K: Experimental models of Parkinson's disease: insights from many models. Lab. Anim. Sci. (1999) 49 (4):363-371.
49. BETARBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. (2000) 3 (12):1301-1306.
50. MASLIAH E, ROCKENSTEIN E, VEINBERGS I et al.: Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science (2000) 287 (5456):1265-1269.
51. VAN DER PUTTEN H, WIEDERHOLD KH, PROBST A et al.: Neuropathology in mice expressing human a-synuclein. J. Neurosci. (2000) 20 (16):6021-6029.
52. KAHLE PJ, NEUMANN M, OZMEN L et al.: Subcellular localization of wild-type and Parkinson's disease-associated mutant a-synuclein in human and transgenic mouse brain. J. Neurosci. (2000) 20(17):6365-6373.
53. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al: Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science (1997) 276 (5321):2045-2047.
54. KRÜGERR, KUHN W, MÜLLERTetal.: Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nature Genet. (1998) 18 (2):106-108.
55. KAHLE PJ, NEUMANN M, OZMEN L, KRETZSCHMAR HA, HAASS C: Somal and neuritic accumulation of the Parkinson's disease-associated mutant [A30P]a-synuclein in transgenic mice. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds.), John Wiley & Sons, Chichester, UK (2001):671-677.
56. FEANY MB, BENDER WW: A Drosophila model of Parkinson's disease. Nature (2000) 404:394-398.
57. LEE MK, BORCHELT DR, WONG PC, SISODIA SS, PRICE DL: Transgenic models of neurodegenerative diseases. Curr. Opin. Neurobiol. (1996) 6 (5):651-660.
58. PRICE DL, SISODIA SS, BORCHELT DR: Genetic neurode generative diseases: the human illness and transgenic models. Science (1998) 282 (5391):1079-1083.